New York State Department of Labor Issues Forms Required When Giving Notice to New Employees Concerning Compensation
Client Alert | 1 min read | 12.17.09
As previously reported in our October 27, 2009 Client Alert, New York Labor Law Section 195(1) was amended, as of October 26, 2009, to require employers in the State of New York to provide newly hired employees, upon their date of hire, with written notification of their regular rate of pay, overtime rate of pay (if applicable) and regular pay dates. Employers are further required to obtain from each employee a written acknowledgement of their receipt of such notice.
On October 28, 2009, the New York State Department of Labor (the "NYDOL") released an official form that employers may use when providing written notices to new employees concerning compensation. Regardless of whether employers use the NYDOL form, some form of notice must be provided to employees at the time of hire prior to performing any work.
The NYDOL is currently preparing additional notice and acknowledgment forms for other categories of employees, such as commissioned salespersons, non-exempt salaried employees and exempt employees. In addition to the forms, the NYDOL will publish guidelines to assist employers in complying with the new requirements. The NYDOL has already published guidelines for temporary employment agencies on its website, along with a notice and acknowledgment form to accommodate pay rates that vary for temporary assignments.
If you have any questions concerning compliance with this new law, please contact the professionals listed below or your regular Crowell & Moring contact.
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
